Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative

Haemonetics Corporation recently presented data at the Heart Rhythm Society 2026 Annual Meeting in Chicago showing its ...

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the publication of a new study ...
Morningstar

Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System

BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ...
Seeking Alpha

Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...
Seeking Alpha

Haemonetics Announces European Expansion for VASCADE® Vascular Closure System

BOSTON, Aug. 29, 2023 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has ...
Endovascular Today

Data Presented From Pilot Trial of InVera Infusion Device for Chronic Venous Disease

InVera Medical announced 12-month results from its pilot clinical study of the InVera infusion device for the treatment of ...
Business Wire

Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal ® Large Hole Closure Device

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced initial positive results from its U.S. IDE ...
TCTMD

TCT 999: ReliaSeal Trial: A Randomized Trial of Multiple Venous Access Closure With MYNX CONTROL™ VENOUS Vascular Closure Device and Manual Compression After Catheter-Based ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Hosted on MSN

Vivasure submits PMA for vascular closure system to FDA

Irish company Vivasure Medical has submitted an application seeking premarket approval (PMA) from the US Food and Drug Administration (FDA) for its PerQseal Elite vascular closure system intended for ...